IPN Ipsen SA

Ipsen : Déclaration des transactions sur actions propres réalisées du 22/06/2020 au 26/06/2020

Regulatory News:

Présentation agrégée par jour et par marché

Nom de

l'émetteur

Code identifiant de

l'émetteur (code LEI)

Jour de la

transaction

Code identifiant de

l'instrument financier

Volume total journalier (en

nombre de titres)

Prix pondéré moyen

journalier

d'acquisition

Code

identifiant

marché

IPSEN

549300M6SGDPB4Z94P11

6/22/2020

FR0010259150

0

-

-

IPSEN

549300M6SGDPB4Z94P11

6/23/2020

FR0010259150

5000

74.3747

XPAR

IPSEN

549300M6SGDPB4Z94P11

6/24/2020

FR0010259150

5000

72.585

XPAR

IPSEN

549300M6SGDPB4Z94P11

6/25/2020

FR0010259150

10000

73.2382

XPAR

IPSEN

549300M6SGDPB4Z94P11

6/26/2020

FR0010259150

2500

76.0558

XPAR

 

 

 

Total

22 500

73.6587

 

L'information détaillée transaction par transaction des opérations réalisées ainsi que les objectifs de rachat sont disponibles sur le site internet de la société à l'adresse suivante:

FR
30/06/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
 PRESS RELEASE

Ipsen delivers strong results in 2025, driven by solid execution acros...

Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance FY 2025 sales growth of 10.9% at CER1, or 8.1% as reported, driven by growth of the three therapeutic areas of Oncology (4.1%1), Rare Disease (102.5%1) and Neuroscience (9.7%1); Somatuline® sales growth of 4.3%1, with all other products, excluding Somatuline, achieving double-digit sales growth of 14.2%1FY 2025 core operating income of €1,294m, growing by 16.7% as reported, with a core operating margin of 35.2% of total sales, increasing by 2.6 points2025 continued pipel...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch